Dr. Nasser H. Zawia is the Qatar Biomedical Research Institute’s (QBRI) Research Director involved in the strategic development of QBRI to guide and support the direction of the institute and oversee the implementation of the research strategy across the institute. He began his official role in 2021 to ensure that the research and scientific activities of QBRI align with recent scientific trends and address the strategic needs of the institute. He is tasked with developing and leading institute-wide scientific research programs and ensuring their successful implementation. He also works to build relationships with public and private entities in Qatar and worldwide to bring strategic value to QBRI.
He has published over 100 papers (Google Scholar: 135+ pubs, Citations approx. 5000, h-index 37, i10-index 72; ResearchGate: RG Score 40 (publication reads about 14,000) and book chapters and has edited a book on Molecular Toxicology and a Journal issue for Current Alzheimer Research.
Dr. Zawia’s research has been supported by the National Institutes of Health NIH, the National Science Foundation (NSF), and the Environmental Protection Agency (EPA). He has chaired NIH grant study sections and also served as a reviewer on many international journals and funding agencies as well as on the editorial board of the Journal of NeuroToxicology, Current Alzheimer Research, and the Journal of Alzheimer’s Disease (JAD).
The Graduate School, University of Rhode Island2011 - 2020
Interdisciplinary Neuroscience Program2011 - 2017
University of Rhode Island1999 - 2020
Meharry Medical College1994 - 1998
National Institute of Health (NIH)1991 - 1994
National Institutes of Health (NIH)
University of California, Irvine, CA
Loma Linda University, Loma Linda, CA
University of Massachusetts, Amherst, MA
Fenamates as Potential Therapeutics for Neurodegenerative Disorders, Cells 10, 702, 2021.2021
Loss in efficacy measures of tolfenamic acid in a tau knock-out model: Relevance to Alzheimer’s disease Experimental Biology and Medicine, 1535370219871249, 2019.2019
Tolfenamic Acid: A Modifier of the Tau Protein and its Role in Cognition and Tauopathy, Current Alzheimer Research 15 (7), 655-663, 2018.2018
Histone acetylation maps in aged mice developmentally exposed to lead: epigenetic drift and Alzheimer-related genes, Epigenomics 10 (5), 573-583, 2018.2018
Unique aspects of the epigenetic code in the brain, Epigenomics, 9 (9), 1157-1159, 2017.2017
Developmental Lead (Pb) Exposure and Lifespan Alterations in Epigenetic Regulators and their Correspondence to Biomarkers of Alzheimer’s Disease. Journal of Alzheimer’s and Dementia DADM, 2, 123-131, 2016.2016
Reduction of Amyloid-β Deposition and Attenuation of Memory Deficits by Tolfenamic Acid. J Alzheimers Dis.;43(2):425-33, 2015.2015